Latest Diabetes News
TUESDAY, Sept. 6, 2016 (HealthDay News) -- An inexpensive medication normally given to people with type 2 diabetes may help preserve heart health in people with the less common form of diabetes -- type 1, a small new study finds.
Metformin is the standard first-line treatment for type 2 diabetes to help bring blood sugar levels down. It also appears to help repair damaged blood cells by increasing the number of blood vessel (vascular) stem cells, researchers said.
"We have shown -- both in test tube and in patients -- the mechanism behind the cardioprotective effects of metformin," said the study's senior author, Dr. Jolanta Weaver. She's a senior lecturer in diabetes medicine at Newcastle University in England.
Sanjoy Duttais is assistant vice president of translational development at JDRF, a nonprofit organization that funds type 1 diabetes research. He expressed enthusiasm for the new findings.
"This was an extremely well-designed and conducted study. They have shown which cardiovascular biomarkers go up and down with metformin. But these are markers only. For a drug to be approved or widely accepted, researchers have to demonstrate hard outcomes," explained Dutta.
JDRF has funded such a study by a different group of researchers that will be done next summer, Dutta said.
Type 1 diabetes is an autoimmune disease that causes the body's immune system to destroy the body's insulin-producing cells. Without sufficient insulin, the body can't process the carbohydrates from food to provide the body's cells with fuel.
Heart disease is the leading cause of premature death in people with type 1 diabetes. Even with good blood sugar control, the risk of heart attack or stroke is twice as high for people with type 1 diabetes compared to people without it, the researchers said.
The new study included 23 adults with type 1 diabetes who were treated with metformin for eight weeks. None had overt signs of heart disease. Their average age was 46.
The starting dose was 500 milligrams (mg) a day, which was increased to 2,000 mg a day if tolerated, Weaver said.
These people were compared to 23 healthy age- and sex-matched volunteers without type 1 diabetes. They were also compared to nine people with type 1 diabetes who weren't given metformin. Their average age was 47.
The people with diabetes were asked to keep their blood sugar control similar to what it was before the metformin. The researchers didn't want an improvement in blood sugar levels to affect the findings.
The researchers saw a number of markers indicating blood vessel repair go up in patients taking metformin. And on the flip side, cells associated with blood vessel damage were reduced in people taking metformin.
Metformin is an older drug, already approved in the United States for treating type 2 diabetes. Brand names include Glumetza, Glucophage, Riomet and Fortamet. The most common side effects are gastrointestinal problems such as nausea and diarrhea.
Dutta said these side effects tend to go away with time. Or, he said, there are medications that can help lessen the side effects.
Weaver said the researchers plan to follow the health of their patients. But, she added, a larger, randomized trial is needed to better know the heart protective effects of metformin in people with type 1 diabetes.
However, because the drug is already approved, doctors can prescribe it "off-label" to patients with type 1 diabetes, Dutta said.
"I am sure doctors will prescribe it at least in a subset of patients who have a very high risk of cardiovascular disease," he said.
Weaver said along with the potential heart protective benefits shown in this study, metformin also helped the patients in the study achieve better blood sugar control, and it helped them lessen variations in blood glucose levels.
Findings from the study were published in Cardiovascular Diabetology.
Copyright © 2016 HealthDay. All rights reserved.
SOURCES: Jolanta Weaver, F.R.C.P., M.R.C.S, Ph.D., senior lecturer, diabetes medicine, Newcastle University, England; Sanjoy Dutta, Ph.D., assistant vice president, translational development, JDRF; Aug. 25, 2016, Cardiovascular Diabetology